Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05013229 · ClinicalTrials.gov registry record · Phase 3
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 679
- Enrollment target
NCT05013229: Completed Phase 3 study, sponsored by Novo Nordisk A/S.
NCT05013229 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 679 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05013229, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 679 participants
- Enrollment target
Study Summary
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin glargine taken daily with insulin aspart in people with type 2 diabetes.The study will look at how well IcoSema controls blood sugar level in people with type 2 diabetes compared to insulin glargine taken with insulin aspart. Participants will either get IcoSema or insulin glargine taken with insulin aspart. Which treatment participants get is decided by chance. IcoSema is a new medicine that doctors cannot prescribe. Doctors can already prescribe insulin glargine and insulin aspart in many countries. Participants will get IcoSema or insulin glargine together with insulin aspart. Participants must inject IcoSema once a week or inject insulin glargine once daily and insulin aspart 2-4 times a day. Participants will inject the medicines with a pen, which has a small needle, in a skin fold in the thigh, upper arm, or stomach. The study will last for about 1 year and 1 month. Participants will be asked to wear a sensor that measures participants blood sugar level all the time during an 8 week period at the beginning of the study and a 4 week period at the end of the study. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.
Primary Outcome
Percent-points
Interventions
- DRUG Insulin glargine
- DRUG insulin aspart
- DRUG IcoSema
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 679 participants |
| Start Date | 2021-11-30 |
| Est. Completion | 2023-11-14 |
| Phase | Phase 3 |
What the finished NCT05013229 record still lists
NCT05013229 is an interventional study that assigns participants to a tested intervention. The registered 679 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% lower).
The record links to 0 conditions, and to 3 interventions - of which Insulin glargine is the first listed.
NCT05013229 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05013229 about?
NCT05013229 is a clinical study titled "A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)". This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin glargine taken daily with insulin aspart in people with type 2 diabetes.The study will look at how well IcoSema controls blood sugar level in people with type 2 d...
What is the current status of trial NCT05013229?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 679 participants. The study started on 2021-11-30. Estimated completion is 2023-11-14.
What interventions are being tested in trial NCT05013229?
The interventions under investigation include: Insulin glargine (DRUG), insulin aspart (DRUG), IcoSema (DRUG).
Who is sponsoring clinical trial NCT05013229?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05013229's enrollment target sits among peer trials
679 536th of 2000 higher than 1,465 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03501706 · 680 participants · NA
An Assessment of Cognitive Improvement Training Among Mid-life Individuals
- NCT05626452 · 680 participants · NA
PrEP Optimization Among Women to Enhance Retention and Uptake
- NCT05753748 · 680 participants · NA
Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
- NCT05952141 · 680 participants · NA
Strategies to Close the Gap From Cervical Cancer Diagnosis to Treatment in Botswana
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI